Adverse event reports following yellow fever vaccination

Vaccine

Volumn 26, Issue 48, 2008, Pages 6077-6082

  Lindsey, Nicole P ^a   Schroeder, Betsy A ^b   Miller, Elaine R ^c   Braun, M Miles ^d   Hinckley, Alison F ^a   Marano, Nina ^b   Slade, Barbara A ^c   Barnett, Elizabeth D ^e   Brunette, Gary W ^b   Horan, Katherine ^b   Staples, J Erin ^a   Kozarsky, Phyllis E ^b,f   Hayes, Edward B ^a  

^a NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^b NATIONAL CENTER FOR PREPAREDNESS DETECTION AND CONTROL OF INFECTIOUS DISEASES   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^e BOSTON MEDICAL CENTER   (United States)

^f EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adverse event; Vaccine; VAERS; Yellow fever

Indexed keywords

YELLOW FEVER VACCINE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; ASTHENIA; CHILD; CHILL; CRITICAL ILLNESS; DISABILITY; DIZZINESS; DRUG FATALITY; DRUG SAFETY; DYSPNEA; FATIGUE; FEMALE; FEVER; HEADACHE; HOSPITALIZATION; HUMAN; INJECTION SITE ERYTHEMA; INJECTION SITE SWELLING; MAJOR CLINICAL STUDY; MALE; MYALGIA; NAUSEA; PAIN; PRIORITY JOURNAL; PRURITUS; RASH; RISK BENEFIT ANALYSIS; SEX DIFFERENCE; SIDE EFFECT; TREATMENT CONTRAINDICATION; URTICARIA; VACCINATION; YELLOW FEVER;

ADOLESCENT; ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; ANAPHYLAXIS; CHILD; CHILD, PRESCHOOL; DATA INTERPRETATION, STATISTICAL; FEMALE; HUMANS; MALE; MIDDLE AGED; PRODUCT SURVEILLANCE, POSTMARKETING; RISK ASSESSMENT; SEX FACTORS; UNITED STATES; VACCINATION; YELLOW FEVER; YELLOW FEVER VACCINE; YOUNG ADULT;

EID: 55249101442     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.09.009     Document Type: Article

References (42)

1. Cetron M.S., Marfin A.A., Julian K.G., Gubler D.J., Sharp D.J., Barwick R.S., et al. Yellow fever vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2002. MMWR Recomm Rep 51 RR-17 (2002) 1-11
2. Monath T.P. Yellow fever vaccine. In: Plotkin S.A., and Orenstein W.A. (Eds). Vaccines. 4th ed. (2004), Elsevier, Philadelphia, PA 1095-1176
3. Lang J., Zuckerman J., Clarke P., Barrett P., Kirkpatrick C., and Blondeau C. Comparison of the immunogenicity and safety of two 17D yellow fever vaccines. Am J Trop Med Hyg 60 6 (1999) 1045-1050
4. Monath T.P., Nichols R., Archambault W.T., Moore L., Marchesani R., Tian J., et al. Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX and YF-VAX) in a phase III multicenter, double-blind clinical trial. Am J Trop Med Hyg 66 5 (2002) 533-541
5. Pfister M., Kursteiner O., Hilfiker H., Favre D., Durrer P., Ennaji A., et al. Immunogenicity and safety of BERNA-YF compared with two other 17D yellow fever vaccines in a phase 3 clinical trial. Am J Trop Med Hyg 72 3 (2005) 339-346
6. Kelso J.M., Mootrey G.T., and Tsai T.F. Anaphylaxis from yellow fever vaccine. J Allergy Clin Immunol 103 4 (1999) 698-701
7. Khromava A.Y., Eidex R.B., Weld L.H., Kohl K.S., Bradshaw R.D., Chen R.T., et al. Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events. Vaccine 23 25 (2005) 3256-3263
8. Martin M., Weld L.H., Tsai T.F., Mootrey G.T., Chen R.T., Niu M., et al. Advanced age a risk factor for illness temporally associated with yellow fever vaccination. Emerg Infect Dis 7 6 (2001) 945-951
9. Lawrence G.L., Burgess M.A., and Kass R.B. Age-related risk of adverse events following yellow fever vaccination in Australia. Commun Dis Intell 28 2 (2004) 244-248
10. Barwick R. History of thymoma and yellow fever vaccination. Lancet 364 9438 (2004) 936
11. Iskander J.K., Miller E.R., and Chen R.T. The role of the vaccine adverse event reporting system (VAERS) in monitoring vaccine safety. Pediatr Ann 33 9 (2004) 599-606
12. Varricchio F., Iskander J., Destefano F., Ball R., Pless R., Braun M.M., et al. Understanding vaccine safety information from the vaccine adverse event reporting system. Pediatr Infect Dis J 23 4 (2004) 287-294
13. Ruggeberg J.U., Gold M.S., Bayas J.M., Blum M.D., Bonhoeffer J., Friedlander S., et al. Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine 25 31 (2007) 5675-5684
14. McMahon A.W., Eidex R.B., Marfin A.A., Russell M., Sejvar J.J., Markoff L., et al. Neurologic disease associated with 17D-204 yellow fever vaccination: a report of 15 cases. Vaccine 25 10 (2007) 1727-1734
15. Zhou W., Pool V., Iskander J.K., English-Bullard R., Ball R., Wise R.P., et al. Surveillance for safety after immunization: vaccine adverse event reporting system (VAERS)-United States, 1991-2001. MMWR Surveill Summ 52 1 (2003) 1-24
16. Cook I.F., Barr I., Hartel G., Pond D., and Hampson A.W. Reactogenicity and immunogenicity of an inactivated influenza vaccine administered by intramuscular or subcutaneous injection in elderly adults. Vaccine 24 13 (2006) 2395-2402
17. Beyer W.E., Palache A.M., Kerstens R., and Masurel N. Gender differences in local and systemic reactions to inactivated influenza vaccine, established by a meta-analysis of fourteen independent studies. Eur J Clin Microbiol Infect Dis 15 1 (1996) 65-70
18. Govaert T.M., Dinant G.J., Aretz K., Masurel N., Sprenger M.J., and Knottnerus J.A. Adverse reactions to influenza vaccine in elderly people: randomised double blind placebo controlled trial. BMJ 307 6910 (1993) 988-990
19. Cook I.F., Pond D., and Hartel G. Comparative reactogenicity and immunogenicity of 23 valent pneumococcal vaccine administered by intramuscular or subcutaneous injection in elderly adults. Vaccine 25 25 (2007) 4767-4774
20. Pittman P.R., Kim-Ahn G., Pifat D.Y., Coonan K., Gibbs P., Little S., et al. Anthrax vaccine: immunogenicity and safety of a dose-reduction, route-change comparison study in humans. Vaccine 20 9-10 (2002) 1412-1420
21. Tuboi S.H., Costa Z.G., da Costa Vasconcelos P.F., and Hatch D. Clinical and epidemiological characteristics of yellow fever in Brazil: analysis of reported cases 1998-2002. Trans R Soc Trop Med Hyg 101 2 (2007) 169-175
22. Hanson H. Observations on the age and sex incidence of deaths and recoveries in the yellow fever epidemic in the department of Lambayeque P, in 1921. Am J Trop Med Hyg 9 (1929) 233-239
23. Gerasimon G., and Lowry K. Rare case of fatal yellow fever vaccine-associated viscerotropic disease. South Med J 98 6 (2005) 653-656
24. Belsher J.L., Gay P., Brinton M., DellaValla J., Ridenour R., Lanciotti R., et al. Fatal multiorgan failure due to yellow fever vaccine-associated viscerotropic disease. Vaccine 25 50 (2007) 8480-8485
25. Doblas A., Domingo C., Bae H.G., Bohorquez C.L., de Ory F., Niedrig M., et al. Yellow fever vaccine-associated viscerotropic disease and death in Spain. J Clin Virol 36 2 (2006) 156-158
26. Vasconcelos P.F., Luna E.J., Galler R., Silva L.J., Coimbra T.L., Barros V.L., et al. Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases. Lancet 358 9276 (2001) 91-97
27. Martin M., Tsai T.F., Cropp B., Chang G.J., Holmes D.A., Tseng J., et al. Fever and multisystem organ failure associated with 17D-204 yellow fever vaccination: a report of four cases. Lancet 358 9276 (2001) 98-104
28. Bae H.G., Domingo C., Tenorio A., Ory F.D., Munoz J., Weber P., et al. Immune response during adverse events after 17D-derived yellow fever vaccination in Europe. J Infect Dis (2008)
29. Adhiyaman V., Oke A., Cefai C., Adhiyaman V., Oke A., and Cefai C. Effects of yellow fever vaccination. Lancet 358 9296 (2001) 1907-1908
30. Werfel U., and Popp W. Effects of yellow fever vaccination. Lancet 358 9296 (2001) 1909
31. Troillet N., and Laurencet F. Effects of yellow fever vaccination. Lancet 358 9296 (2001) 1908-1909
32. Struchiner C.J., Luz P.M., Dourado I., Sato H.K., Aguiar S.G., Ribeiro J.G., et al. Risk of fatal adverse events associated with 17DD yellow fever vaccine. Epidemiol Infect 132 5 (2004) 939-946
33. Zhou Q., Liu D.W., Shi Y., Long Y., Li D.J., Liu H.Z., et al. Adverse effects of attenuated yellow fever vaccine with multiple organ injury-a case report. Zhonghua Yi Xue Za Zhi 85 13 (2005) 936
34. Vellozzi C., Mitchell T., Miller E., Casey C.G., Eidex R.B., and Hayes E.B. Yellow fever vaccine-associated viscerotropic disease (YEL-AVD) and corticosteroid therapy: eleven United States cases, 1996-2004. Am J Trop Med Hyg 75 2 (2006) 333-336
35. Pulendran B., Miller J., Querec T.D., Akondy R., Moseley N., Laur O., et al. Case of yellow fever vaccine-associated viscerotropic disease with prolonged viremia, robust adaptive immune responses, and polymorphisms in CCR5 and RANTES genes. J Infect Dis 198 4 (2008) 500-507
36. Chan R.C., Penney D.J., Little D., Carter I.W., Roberts J.A., and Rawlinson W.D. Hepatitis and death following vaccination with 17D-204 yellow fever vaccine. Lancet 358 9276 (2001) 121-122
37. Engel A.R., Vasconcelos P.F., McArthur M.A., and Barrett A.D. Characterization of a viscerotropic yellow fever vaccine variant from a patient in Brazil. Vaccine 24 15 (2006) 2803-2809
38. Munoz J., Vilella A., Domingo C., Nicolas J.M., de Ory F., Corachan M., et al. Yellow fever-associated viscerotropic disease in Barcelona. Spain. J Travel Med 15 3 (2008) 202-205
39. CDC. Adverse events associated with 17D-derived yellow fever vaccination-United States, 2001-2002. MMWR 2002;51(44):989-93.
40. CDC. Health information for international travel 2008. Atlanta: US Department of Health and Human Services PHS; 2007.
41. Monath T.P., and Cetron M.S. Prevention of yellow fever in persons traveling to the tropics. Clin Infect Dis 34 10 (2002) 1369-1378
42. Rosenthal S., and Chen R. The reporting sensitivities of two passive surveillance systems for vaccine adverse events. Am J Public Health 85 12 (1995) 1706-1709